EMN19

Title

Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for Treatment of Myeloma Patients Presenting with Extramedullary Disease. The Antares Study

Overview / Summary

 

 

Study details

Patient eligibility criteria

1. Newly Diagnosed or 1st relapse MM patients with EMN (paraskeletal plasmacytomas ONLY are not eligible)
2. ECOG PS ≤ 2. Note: for subjects with CNS involvement, an ECOG PS > 2 is also acceptable
3. Measurable Disease (Serum. urine or sFLC MM)
4. Non refractory to bortezomib based regimens
5. No prior treatment with anti-CD38 or anti-CS1 MoAB
6. Adequate Bone Marrow function (minimum laboratory requirements)
7. No ASCT within 12 weeks of C1D1
8. No prior allo-SCT (regardless of timing)

Publications